OncLive® On Air
OncLive® On Air
In OncLive® On Air, you can expect to hear interviews with academic oncologists on the thought-provoking oncology presentations they give at the OncLive® State of the Science Summits. The topics in oncology vary, from systemic therapies, surgery, radiation therapy, to emerging therapeutic approaches in a particular type of cancer. This includes lung cancer, breast cancer, gastrointestinal cancers, hematologic malignancies, gynecologic cancers, genitourinary cancers, and more.
Episodes
Mentioned books
Nov 14, 2022 • 14min
S7 Ep47: FDA Approval Insights: Teclistamab in Relapsed/Refractory Multiple Myeloma
Dr Garfall discusses the FDA approval of teclistamab in relapsed/refractory multiple myeloma, key efficacy and safety data from the MajesTEC-1 trial, and the drug’s unique mechanism of action compared with other anti-myeloma agents.
Nov 10, 2022 • 26min
S7 Ep46: Lunning Lends Insight on Pivotal Data From Pan Pacific Lymphoma 2022
In this inaugural episode, Dr Lunning details important findings to come out of the Pan Pacific Lymphoma Conference, including results evaluating prophylactic medications in the management of patients with hematologic malignancies receiving cellular therapy or autologous stem cell transplant.
Nov 7, 2022 • 22min
S7 Ep45: Sauter and Hill Talk Through CAR T Cell Sequencing and Access in Lymphomas
Drs Sauter and Hill discuss the use of CAR T-cell therapy in patients with lymphomas, the potential for allogeneic CAR T cells, and ways to expand access and address financial toxicity.
Nov 3, 2022 • 11min
S7 Ep44: FDA Approval Insights: Futibatinib in FGFR2-Positive Cholangiocarcinoma
Dr Goyal discusses the FDA approval of futibatinib in FGFR2-positive cholangiocarcinoma, key safety data from the FOENIX*-CCA2 trial, and the importance of biomarker testing in the cholangiocarcinoma population.
Oct 31, 2022 • 22min
S7 Ep43: Thymic Cancer Experts Discuss the Latest Data, Need for More Research Funding
Drs Giaccone and He discuss the implications of their thymic cancer research, the importance of combining immunotherapy and anti-angiogenesis agents to treat solid tumors, and the challenges of investigating rare cancers.
Oct 27, 2022 • 15min
S7 Ep42: Mikhael and Cole Share Insights on Culturally Relevant Myeloma Care
Drs Mikhael and Cole discuss ways to help reduce disparities in myeloma by delivering culturally relevant care and highlight the importance of implementing shared decision-making, creating a well-informed multidisciplinary staff, and meeting patients where they are.
Oct 24, 2022 • 16min
S7 Ep41: FDA Approval Insights: Sodium Thiosulfate in Cisplatin-Treated Pediatric Solid Tumors
Dr Shah discusses the FDA approval of sodium thiosulfate in pediatric patients with solid tumors treated with cisplatin, key efficacy and safety data from the SIOPEL6 and COG ACCL0431 trials, and the importance of multidisciplinary communication when prescribing and administering the agent.
Oct 20, 2022 • 47min
S7 Ep40: Leukemia Experts Discuss Early Career Growth, Mentorship, and Gender Bias in Academia
Drs DiNardo, Wang, and Altman discuss the challenges they faced in their early careers, the rollout of molecular profiling and targeted therapy in the early 2000s, and their growth from protégés to mentors.
Oct 17, 2022 • 15min
S7 Ep39: Community Perspectives on Integrating and Interpreting Molecular Testing Results in NSCLC
Drs Ramkumar and Morganstein discuss the challenges they face with integrating and organizing molecular testing results into electronic medical records, how they address non–small cell lung cancer test results with patients, and their hopes for the future of pathology at their institutions.
Oct 13, 2022 • 19min
S7 Ep38: FDA Approval Insights: Selpercatinib in RET Fusion–Positive Solid Tumors
Dr Subbiah discusses the significance of the FDA approval of selpercatinib in RET fusion–positive non–small cell lung cancer, thyroid cancer, and other solid tumors.
